Table 1. Primary bone tumors of skull diagnosed over a 12-year period.
| Tumors | Number of cases (% of all tumors) | Age distribution (y): Median (range) | Male:female ratio | Most common location (number) |
|---|---|---|---|---|
| Malignant tumors | ||||
| Chordoma | 43 (34.4%) | 35 (4–60) | 36:7 | Clivus (28) |
| Chondrosarcoma | 37 (29.6%) | 32 (15–60) | 24:13 | Skull base (31) |
| Plasmacytoma | 7 (5.6%) | 54 (40–65) | 5:2 | Skull base (3) |
| Osteosarcoma | 5 (4%) | 22 (15–28) | 3:2 | Frontal bone (2) |
| ES/pPNET | 4 (3.2%) | 9.5 (2–13) | 3:1 | Parietal bone (2) |
| LCH | 2 (1.6%) | 15.5 (2–29) | 1:1 | Parietal and occipital bones |
| Tumors with intermediate malignant potential (rarely metastasizing) | ||||
| GCT | 9 (7.2%) | 32 (18–42) | 6:3 | Clivus (6) |
| Benign tumors | ||||
| Osteoma | 7 (5.6%) | 23 (14–35) | 4:3 | Frontal (3), parietal (3) |
| ABC | 4 (3.2%) | 27 (4–47) | 3:1 | Temporal (3) |
| Hemangioma | 2 (1.6%) | 17 (9–25) | Males | Frontal, temporal |
| Chondromyxoid fibroma | 1 (0.8%) | 35 | Female | Skull base |
| Osteoid osteoma | 1 (0.8%) | 16 | Male | Orbit |
| Ossifying fibroma | 1 (0.8%) | 11 | Male | Orbit |
| Cementoossifying fibroma | 1 (0.8%) | 13 | Male | Orbit |
| Fibrous dysplasia | 1 (0.8%) | 33 | Male | Orbit |
Abbreviations: ABC, aneurysmal bone cyst; ES, Ewing sarcoma; GCT, giant cell tumor; LCH, Langerhan cell histiocytosis; pPNET, peripheral primitive neuroectodermal tumor.